Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.0552W HIGH $45.50
Volume
2.53 K
Value Traded
2.36 M
Short % Float
2.11%
Days to Cover
1.0
-4.87%Week
-44.59%1 Month
-69.17%3 Month
-92.25%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.75 M
EPS (TTM)
-5.09
P/E Ratio
-
Ent. Value
3.83 M
Total Shares
2.69 M
Float Shares
2.46 M
Insiders
8.38%
Institutions
1.15%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
TNON Catalyst Timeline
Dated clinical, regulatory and corporate events for Tenon Medical, Inc.
Past FDA Catalysts and PDUFA Decisions
How TNON actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Tenon Medical, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TNON program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HRT FINANCIAL LP10% Owner | Buy | 31,227 15,839 held | $2.92 | 09/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TNON
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TNON for Q2 2026. | ||||
Ownership Trends
TNON Short Interest
Shares sold short, counted twice a month.
2.11%
Short % of Float
of tradable shares sold short
51.8K
Shares Sold Short
-14.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
895.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TNON ranks across every disease it competes in
Competitive Position is a premium feature
See how TNON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTNON News
-TNON
Aug 28, 2026WallachBeth Capital Announces Tenon Medical Pricing of $3M Private Placement Offering
Tenon Medical, Inc. has announced a $3 million private placement offering led by WallachBeth Capital. The offering involves the sale of 597,610 shares of common stock and warrants for additional shares. The expected closing date is August 31, 2026, subject to customary conditions. The securities will be sold under private placement regulations.
Read more →-TNON
Aug 28, 2026Tenon Medical Announces Pricing of $3M Private Placement Offering
Tenon Medical, Inc. has announced a $3 million private placement offering, entering into a securities purchase agreement with an institutional investor. The offering includes 597,610 shares of common stock and warrants for additional shares, with an effective price of $5.02 per share. The transaction is expected to close by August 31, 2026, pending customary conditions.
Read more →-TNON
May 13, 2026▼ -11.5%on this news
Tenon(R) Medical Reports First Quarter 2026 Financial Results
Tenon Medical reported a substantial increase in its first quarter 2026 financial results, with revenue reaching $1.4 million, a 90% rise compared to the previous year. The gross profit also saw a significant increase of 193%, leading to a gross margin of 68.5%. The company closed a $4.3 million private placement to support its commercial expansion and product development efforts. Despite a net loss of $3.5 million, the company is optimistic about its growth trajectory and plans to continue expanding its surgical offerings.
Read more →-TNON
May 12, 2026Tenon Medical Reports First Quarter 2026 Financial Results ~ First Quarter 2026 Revenue of $1.4 Million, an Increase of Approximately 90% Compared to Prior Year ~ ~ First Quarter Gross Profit of $0.9 Million, an Increase
Tenon Medical reported strong financial results for the first quarter of 2026, with a revenue of $1.4 million, up nearly 90% from the previous year. Gross profit also saw a significant increase of approximately 193%, leading to a gross margin improvement to 68.5%. The company focused on expanding its surgical systems and increasing surgeon engagement. However, while revenues grew, operating expenses also increased, leading to a net loss of $3.5 million.
Read more →-TNON
Mar 20, 2026Tenon(R) Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Tenon Medical reported significant financial growth for Q4 and full year 2025, with revenues reaching $1.5 million in Q4, a 92% increase year-over-year. The company also achieved FDA clearance for its SImmetry+ SI Joint Fusion System, enhancing its market position. Despite a net loss of $2.8 million in Q4, the company is optimistic about future growth driven by increased surgeon adoption and a strengthened balance sheet.
Read more →-TNON
Mar 19, 2026Tenon Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Tenon Medical reported significant financial results for the fourth quarter and full year of 2025, with Q4 revenue reaching $1.5 million, a 92% increase from 2024. The full year revenue also marked a record at $3.9 million, up 20% year-over-year, primarily driven by increased surgical procedures. The company received FDA clearance for its new SImmetry + SI joint fusion system and has begun procedures, enhancing its competitive position. However, the company reported a net loss in Q4, although showing improvement compared to previous losses.
Read more →-TNON
Mar 12, 2026Tenon Medical Announces Closing of Private Placement of Senior Convertible Notes Offering for Gross Proceeds of $ 4.3 Million LOS GATOS, CA / ACCESS Newswire /
Tenon Medical, Inc. has announced the closing of a private placement of senior convertible notes, generating gross proceeds of $4.3 million. The financing aims to support various initiatives, including commercial expansion and clinical studies. The notes have a maturity date set for September 11, 2026, and can be converted into shares of common stock at a predefined price. This move reflects Tenon's strategic efforts to enhance its position in the medical device market, particularly in treating sacro-pelvic disorders.
Read more →-TNON
Feb 18, 2026▲ +5.3%on this news
Tenon(R) Medical Strengthens Intellectual Property Portfolio with Strategic Patent Expansion
Tenon Medical, Inc. has announced a strategic expansion of its U.S. intellectual property portfolio, receiving Notices of Allowance for multiple patent applications. This expansion builds on ten patents issued in 2025 and strengthens protection for its Catamaran SI Joint Fusion System. The company aims to enhance its competitive position and drive long-term growth through continued innovation and diversification of its patent assets.
Read more →-TNON
Feb 5, 2026Tenon Medical, Inc. Sets Date for Fourth Quarter and Full Year 2025 Earnings, Reaffirms Expected Revenues
Tenon Medical, Inc. has announced its plans to release financial results for the fourth quarter and full year 2025 on March 19, 2026. The company anticipates a revenue of $1.45 to $1.48 million for Q4 2025, reflecting a significant growth of approximately 90% compared to the previous year. Additionally, the full year revenue is expected to be between $3.91 to $3.94 million, indicating a 20% year-over-year increase.
Read more →-TNON
Jan 29, 2026Tenon(R) Medical Issues Shareholder Letter and Provides Preliminary Revenue for the Fourth Quarter and Full Year 2025
Tenon Medical reported strong preliminary revenue growth for Q4 and full year 2025, with Q4 revenue estimated at $1.45 to $1.48 million, reflecting a 90% increase year-over-year. The company highlighted significant milestones, including the acquisition of SiVantage technologies and FDA clearance for its Catamaran SI Joint Fusion System. Looking ahead, Tenon aims to leverage its expanded product portfolio for sustained growth in 2026.
Read more →-TNON
Nov 11, 2025Tenon Medical Announces Pricing of At-The-Market ~ Strategically Placed PIPE With Industry Supportive
Tenon Medical, Inc. has announced the pricing of an at-the-market private investment in public equity (PIPE) financing, garnering $2.85 million in gross proceeds. The PIPE is backed by several accredited investors, indicating strong support from strategic industry partners. The company plans to use the funds for working capital, expansion of commercial operations, and advancement of clinical studies, positioning itself for future growth in sacro-pelvic disorder treatments.
Read more →-TNON
Aug 1, 2025▲ +43.1%on this news
Tenon Medical Expands Sacro-Pelvic Fusion Portfolio with Strategic Asset Acquisition
Tenon Medical, Inc. has announced a strategic asset acquisition from SiVantage, enhancing its capabilities in sacro-pelvic fusion technology. This acquisition includes SiVantage's SImmetry and SImmetry+ technologies, which will allow for customized treatment plans for patients with sacroiliac joint disorders. The deal positions Tenon Medical as a leader in the rapidly evolving sacro pelvic fusion market, focusing on innovative solutions backed by clinical data.
Read more →-TNON
Mar 25, 2025▲ +283.4%on this news
Tenon Medical, Inc. Announces a $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Tenon Medical, Inc. has announced a $2.5 million registered direct offering and a concurrent private placement priced at-the-market. The company will issue 1,271,500 shares of common stock and warrants to an institutional investor, with proceeds intended for working capital and general corporate purposes. The closing of the offering is expected by March 27, 2025, pending customary conditions. Tenon is known for its innovative approach to treating sacroiliac joint disorders.
Read more →-TNON
Mar 25, 2025▲ +283.4%on this news
Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Tenon Medical, Inc. has announced a registered direct offering and a concurrent private placement with a single institutional investor, targeting the issuance of 733,500 shares at $2.00 each. The expected gross proceeds of around $1.5 million will be allocated towards working capital and corporate purposes. The completion of the offering is anticipated on or about March 26, 2025, pending customary closing conditions. This initiative follows the company's recent focus on the Catamaran SI Joint Fusion System for treating sacroiliac joint disorders.
Read more →-TNON
Sep 12, 2024▲ +43.8%on this news· ran to +147% by day 1
Tenon Medical, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Tenon Medical, Inc. has announced a public offering priced at $4.5 million under Nasdaq rules. This offering involves the sale of up to 1,222,850 shares and warrants at $3.68 per share, expected to close by September 16, 2024. The funds will be allocated towards commercial activities and working capital, enhancing the company’s operations in sacroiliac joint disorders. The offering's regulatory aspects were confirmed by the SEC's approval of the registration statement.
Read more →-TNON
Aug 27, 2024▲ +5.6%on this news
Tenon Medical Appoints Medical Device Veteran, Kevin Williamson, Chief Financial Officer Los Gatos, CA
Tenon Medical, Inc. has appointed Kevin Williamson as its new Chief Financial Officer, succeeding Steve Van Dick. Williamson brings a wealth of experience from his previous positions in medical device companies, specifically in finance and operational oversight. His appointment aligns with key milestones for Tenon, including the full enrollment of a clinical trial for their Catamaran SI Joint Fusion System. This strategic leadership change is anticipated to help the company advance its market objectives and growth plans in addressing sacroiliac joint disorders.
Read more →-TNON
Mar 28, 2024▲ +5.5%on this news
Experienced Medical Devices Industry Executive Joins Tenon's Board
Tenon Medical, Inc. has appointed Kristine Jacques to its Board of Directors, effective immediately. With over 35 years of experience in the medical devices industry, Jacques is expected to contribute valuable insights aimed at advancing Tenon's commercialization strategy for its Catamaran SI Joint Fusion System. The appointment adds depth to the board, which now consists of seven members, including four independent directors. Jacques's expertise in product management and market strategies could be pivotal as the company navigates toward growth and expansion in its offerings.
Read more →-TNON
Mar 12, 2024Tenon Medical Reports Fourth Quarter and Full Year 2023 Financial Results ~ Fourth Quarter 2023 Revenue Increased 192% Year-Over-Year ~ ~ Full Year 2023 Revenue Increased 324% Year-Over-Year ~ ~ Surgical Procedures Incre
Tenon Medical reported impressive financial results for the fourth quarter and full year of 2023, with Q4 revenue climbing by 192% year-over-year to reach $808,000. Full year revenue also saw a substantial increase of 324%, amounting to $2.9 million, driven by a 312% jump in surgical procedures using the Catamaran SI Joint Fusion System. The company achieved positive gross profit margins for three consecutive quarters, reflecting strong operational progress. Despite these successes, net losses were reported at $15.6 million for the year, with expectations of additional losses in the near future.
Read more →-TNON
Feb 21, 2024Tenon Medical, Inc. Issues Approximately $3.85 Million in Series A Preferred Stock
Tenon Medical, Inc. has successfully closed a private placement of approximately $2.6 million through the issuance of Series A Preferred Stock and warrants. The company plans to use these funds for growth investments, working capital, and general corporate purposes. Additionally, Tenon announced the retirement of $1.25 million in secured debt via the exchange of notes for preferred stock. The company's innovative Catamaran SI Joint Fusion System continues to expand its market opportunities.
Read more →-TNON
Jan 10, 2024Tenon Medical, Inc. Announces Second Adjournment of Special Meeting of Stockholders Meeting adjourned to Tuesday
Tenon Medical, Inc. announced the adjournment of its Special Meeting of Stockholders to January 30, 2024, to allow for additional time to gather votes on Proposal 2. The proposal involves amending the Certificate of Incorporation and requires a majority vote from the outstanding shares. Tenon's Board recommends support for the proposal, emphasizing that a lack of response is viewed as opposition. Stockholders remain eligible to vote regardless of whether they have sold their shares since the record date established on November 9, 2023.
Read more →About Tenon Medical, Inc.
Headquarters104 COOPER CT., LOS GATOS, CA, 95032
BIOPHARMAWATCH ELITE PLUS
Trade the next TNON catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime